Dupilumab
Stories
-
Sanofi registers Phase 3 study of dupilumab coformulation in atopic dermatitis
The study, led by Sanofi and collaborating with Regeneron Pharmaceuticals, plans to enroll 150 participants and begin on November 30, 2026. It compares the pharmacokinetics, immunogenicity and safety of dupilumab coformulated with berahyaluronidase alfa to the approved dupilumab formulation in adults and adolescents with moderate-to-severe atopic dermatitis.